+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Autoinjectors Market By Type, By Application, By End Use, By Region, Industry Analysis and Forecast, 2020 - 2026

  • ID: 5233810
  • Report
  • December 2020
  • Region: Global
  • 205 pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie, Inc.
  • Amgen, Inc.
  • Biogen, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC (GSK)
  • Merck Group
The Global Autoinjectors Market size is expected to reach $5.3 billion by 2026, rising at a market growth of 17.6% CAGR during the forecast period. An autoinjector is a medical device consist of a syringe having a spring-charged needle containing a pre-charged dosage of drugs and is designed to administer a dose of a specific drug. These injectors were primarily designed to overcome the fear related to the needle-based drug delivery device used for self-administration.

The system activates and administers a measured amount of a drug when pushed into the body of the subject with a downward motion. Autoinjectors are extensively used for self-administration of epinephrine in order to prevent anaphylaxis. Epinephrine is taken by migraine sufferers to get immediate pain relief and also for other medical emergency treatments. Auto-injectors have multiple benefits including reducing needle-related phobia disorder, decreases the risks of needle jammed accidents, make sure dosage quality steadiness, and serving increase effectiveness.

The auto-injector market is likely to register considerable growth in the coming years, due to increased cases of anaphylaxis. In addition to it, there is a rapid rise in R&D efforts by manufacturing companies. These efforts are in direction to develop simple, cost-effective, and novel technology-based autoinjectors that can be used for the treatment of chronic diseases including rheumatoid arthritis and multiple sclerosis. Such developments are anticipated to drive the market growth during the forecast period.

By Type

Based on Type, the market is segmented into Disposable autoinjectors and Reusable autoinjectors. The disposable autoinjectors segment had the largest share of the global market of autoinjectors in 2019. Disposable autoinjectors are preferred mostly owing to their ease of use and also the presence of the built-in glass syringe eliminates the necessity of manually filling the glass syringe, which makes it more suitable for patients with visual impairments or reduced dexterity.

autoinjectors-market-share.jpg

By Application

Based on Application, the market is segmented into Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications. In 2019, Anaphylaxis segment had the largest share of the autoinjectors market. This is mainly accredited to its high occurrence. The growing incidence of rheumatoid arthritis also drives the demand for autoinjectors worldwide. As per the CDC, around 43.7 million adults which comprise 22.7% of the total population of the US are affected by some form of arthritis such as RA, lupus, gout, or fibromyalgia annually.

autoinjectors-market-size.jpg

By End Use

Based on End Use, the market is segmented into Hospitals & Clinics and Home care settings. The hospital segment is expected to grow at faster pace in the coming years due to a surge in the number of patients who are suffering from multiple sclerosis and anaphylaxis. Multiple sclerosis is very common in the U.S., Europe, Canada, and New Zealand. It affects more than 400,000 people alone in the U.S. and about 2.5 million people all across the globe.

By Region

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. The growth of the market in the Asia Pacific market is largely due to the large number of patients suffering from chronic allergies and diabetes as well as increasing healthcare expenditure. This in turn has drawn a number of key auto-injector device manufacturers to this region. These companies are showing more presence in the Asia Pacific market via several approaches, including partnering with local pharmaceutical companies and establishing sales offices. The growing occurrence of type 1 diabetes is expected to drive market growth.

autoinjectors-market-competition-analysis.jpg
The major strategies followed by the market participants are Product Launches and Partnerships. Based on the Analysis presented in the Cardinal matrix; Amgen, Inc., Biogen, Inc., and GlaxoSmithKline PLC, Company are the forerunners in the Auto-Injectors Market. Companies such as Sanofi S.A., Teva Pharmaceuticals Industries Ltd., Becton, Dickinson and Company, Ypsomed AG, and Merck Group are some of the key innovators in the market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly and Company, GlaxoSmithKline PLC (GSK), Merck Group, Sanofi S.A., Becton, Dickinson and Company, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., Ypsomed AG, AbbVie, Inc. and Biogen, Inc.

Strategies deployed in Auto-Injectors Market

Partnerships, Collaborations, and Agreements:

Nov-2020: Eli Lilly signed an agreement with Ypsomed. The agreement aimed to advance an automated insulin delivery system as a part of Lilly's connected diabetes solution. Under this agreement, Lilly commercialized the system that includes an insulin pump developed and manufactured by Ypsomed.

Jun-2020: Teva collaborated with Schreiner MediPharm. The collaboration aims to develop an Auto injector-Label with special protection against abrasion for the allergy emergency drug epinephrine from Teva. The label developed by Schreiner MediPharm for Teva’s adrenaline injector provided with abrasion- and scratch-resistant reverse printing.

Jul-2019: Teva Pharmaceutical collaborated with Ypsomed. The companies together introduced the drug product Copaxone, which is used for the treatment of patients with relapsing forms of multiple sclerosis.

Jun-2019: Sanofi entered into a partnership with Enable Injections. The partnership aimed to include multiple molecule development programs incorporating long-term manufacturing and supply arrangements.

Jun-2018: AbbVie teamed up with Eisai. The companies aimed to launch the autoinjection delivery system for HUMIRA. HUMIRA, a pen-type auto-injector device developed to simplify the operation and reduce the burden on patients when performing self-injection.

Jan-2018: Biogen collaborated with Eisai. The collaboration focused on the promotion of Biogen's multiple sclerosis treatments TECFIDERA, TYSABRI, and AVONEX in Japan.

Product Launches and Product Expansions:

Oct-2020: Sanofi introduced Tetraxim, a new booster vaccine. This booster vaccine combined four vaccines for reducing the number of injections, increasing comfort, and enhancing vaccination compliance for children. Tetraxim is indicated for preschoolers and offers protection against four major diseases namely diphtheria, pertussis, tetanus, and polio.

Apr-2020: Teva Pharmaceuticals launched the auto-injector device for AJOVY injection in the U.S. AJOVY indicated the preventive treatment of migraine in adults and the only anti-CGRP preventive migraine treatment with quarterly and monthly subcutaneous dosing options.

Oct-2019: Becton, Dickinson, and Company introduced the BD Intevi 1mL two-step disposable auto-injector. The auto-injector is a two-step push-on-skin device that is designed to effectively and safely inject various drugs of different viscosities up to 35cP and different fill volumes up to 1mL.

Aug-2019: Teva Pharmaceutical launched an FDA-approved generic version of EpiPen Jr 1 Auto-Injector, 0.15 mg, in the U.S.

Approvals:

Jan-2020: Sanofi got the approval of a 300 mg single-dose pre-filled pen for Dupixent by the U.S. Food and Drug Administration. The new pre-filled pen provided patients with a more convenient option for administering Dupixent.

Jan-2020: Teva Pharmaceutical received approval from the U.S. Food and Drug Administration for Ajovy, an auto-injector for its migraine-treatment drug.

Jun-2019: GlaxoSmithKline got approval from the US Food and Drug Administration (FDA) for two new methods for administering Nucala (mepolizumab). Nucala is an auto-injector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after discussing it with healthcare professionals.

Scope of the Study

Market Segments covered in the Report:

By Type
  • Disposable autoinjectors
  • Reusable autoinjectors
By Application
  • Anaphylaxis
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Other Applications
By End Use
  • Hospitals & Clinics
  • Home care settings
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Eli Lilly and Company
  • GlaxoSmithKline PLC (GSK)
  • Merck Group
  • Sanofi S.A.
  • Becton, Dickinson and Company
  • Teva Pharmaceuticals Industries Ltd.
  • Amgen, Inc.
  • Ypsomed AG
  • AbbVie, Inc.
  • Biogen, Inc.
Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie, Inc.
  • Amgen, Inc.
  • Biogen, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC (GSK)
  • Merck Group
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Autoinjectors Market, by Type
1.4.2 Global Autoinjectors Market, by Application
1.4.3 Global Autoinjectors Market, by End Use
1.4.4 Global Autoinjectors Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Geographical Expansions
3.2.4 Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2016, May - 2020, Nov) Leading Players

Chapter 4. Global Autoinjectors Market by Type
4.1 Global Disposable autoinjectors Market by Region
4.2 Global Reusable autoinjectors Market by Region

Chapter 5. Global Autoinjectors Market by Application
5.1 Global Anaphylaxis Market by Region
5.2 Global Rheumatoid Arthritis Market by Region
5.3 Global Multiple Sclerosis Market by Region
5.4 Global Other Application Market by Region

Chapter 6. Global Autoinjectors Market by End Use
6.1 Global Hospitals & Clinics Autoinjectors Market by Region
6.2 Global Home care settings Autoinjectors Market by Region

Chapter 7. Global Autoinjectors Market by Region
7.1 North America Autoinjectors Market
7.1.1 North America Autoinjectors Market by Type
7.1.1.1 North America Disposable autoinjectors Market by Country
7.1.1.2 North America Reusable autoinjectors Market by Country
7.1.2 North America Autoinjectors Market by Application
7.1.2.1 North America Anaphylaxis Market by Country
7.1.2.2 North America Rheumatoid Arthritis Market by Country
7.1.2.3 North America Multiple Sclerosis Market by Country
7.1.2.4 North America Other Application Market by Country
7.1.3 North America Autoinjectors Market by End Use
7.1.3.1 North America Hospitals & Clinics Autoinjectors Market by Country
7.1.3.2 North America Home care settings Autoinjectors Market by Country
7.1.4 North America Autoinjectors Market by Country
7.1.4.1 US Autoinjectors Market
7.1.4.1.1 US Autoinjectors Market by Type
7.1.4.1.2 US Autoinjectors Market by Application
7.1.4.1.3 US Autoinjectors Market by End Use
7.1.4.2 Canada Autoinjectors Market
7.1.4.2.1 Canada Autoinjectors Market by Type
7.1.4.2.2 Canada Autoinjectors Market by Application
7.1.4.2.3 Canada Autoinjectors Market by End Use
7.1.4.3 Mexico Autoinjectors Market
7.1.4.3.1 Mexico Autoinjectors Market by Type
7.1.4.3.2 Mexico Autoinjectors Market by Application
7.1.4.3.3 Mexico Autoinjectors Market by End Use
7.1.4.4 Rest of North America Autoinjectors Market
7.1.4.4.1 Rest of North America Autoinjectors Market by Type
7.1.4.4.2 Rest of North America Autoinjectors Market by Application
7.1.4.4.3 Rest of North America Autoinjectors Market by End Use
7.2 Europe Autoinjectors Market
7.2.1 Europe Autoinjectors Market by Type
7.2.1.1 Europe Disposable autoinjectors Market by Country
7.2.1.2 Europe Reusable autoinjectors Market by Country
7.2.2 Europe Autoinjectors Market by Application
7.2.2.1 Europe Anaphylaxis Market by Country
7.2.2.2 Europe Rheumatoid Arthritis Market by Country
7.2.2.3 Europe Multiple Sclerosis Market by Country
7.2.2.4 Europe Other Application Market by Country
7.2.3 Europe Autoinjectors Market by End Use
7.2.3.1 Europe Hospitals & Clinics Autoinjectors Market by Country
7.2.3.2 Europe Home care settings Autoinjectors Market by Country
7.2.4 Europe Autoinjectors Market by Country
7.2.4.1 Germany Autoinjectors Market
7.2.4.1.1 Germany Autoinjectors Market by Type
7.2.4.1.2 Germany Autoinjectors Market by Application
7.2.4.1.3 Germany Autoinjectors Market by End Use
7.2.4.2 UK Autoinjectors Market
7.2.4.2.1 UK Autoinjectors Market by Type
7.2.4.2.2 UK Autoinjectors Market by Application
7.2.4.2.3 UK Autoinjectors Market by End Use
7.2.4.3 France Autoinjectors Market
7.2.4.3.1 France Autoinjectors Market by Type
7.2.4.3.2 France Autoinjectors Market by Application
7.2.4.3.3 France Autoinjectors Market by End Use
7.2.4.4 Russia Autoinjectors Market
7.2.4.4.1 Russia Autoinjectors Market by Type
7.2.4.4.2 Russia Autoinjectors Market by Application
7.2.4.4.3 Russia Autoinjectors Market by End Use
7.2.4.5 Spain Autoinjectors Market
7.2.4.5.1 Spain Autoinjectors Market by Type
7.2.4.5.2 Spain Autoinjectors Market by Application
7.2.4.5.3 Spain Autoinjectors Market by End Use
7.2.4.6 Italy Autoinjectors Market
7.2.4.6.1 Italy Autoinjectors Market by Type
7.2.4.6.2 Italy Autoinjectors Market by Application
7.2.4.6.3 Italy Autoinjectors Market by End Use
7.2.4.7 Rest of Europe Autoinjectors Market
7.2.4.7.1 Rest of Europe Autoinjectors Market by Type
7.2.4.7.2 Rest of Europe Autoinjectors Market by Application
7.2.4.7.3 Rest of Europe Autoinjectors Market by End Use
7.3 Asia Pacific Autoinjectors Market
7.3.1 Asia Pacific Autoinjectors Market by Type
7.3.1.1 Asia Pacific Disposable autoinjectors Market by Country
7.3.1.2 Asia Pacific Reusable autoinjectors Market by Country
7.3.2 Asia Pacific Autoinjectors Market by Application
7.3.2.1 Asia Pacific Anaphylaxis Market by Country
7.3.2.2 Asia Pacific Rheumatoid Arthritis Market by Country
7.3.2.3 Asia Pacific Multiple Sclerosis Market by Country
7.3.2.4 Asia Pacific Other Application Market by Country
7.3.3 Asia Pacific Autoinjectors Market by End Use
7.3.3.1 Asia Pacific Hospitals & Clinics Autoinjectors Market by Country
7.3.3.2 Asia Pacific Home care settings Autoinjectors Market by Country
7.3.4 Asia Pacific Autoinjectors Market by Country
7.3.4.1 China Autoinjectors Market
7.3.4.1.1 China Autoinjectors Market by Type
7.3.4.1.2 China Autoinjectors Market by Application
7.3.4.1.3 China Autoinjectors Market by End Use
7.3.4.2 Japan Autoinjectors Market
7.3.4.2.1 Japan Autoinjectors Market by Type
7.3.4.2.2 Japan Autoinjectors Market by Application
7.3.4.2.3 Japan Autoinjectors Market by End Use
7.3.4.3 India Autoinjectors Market
7.3.4.3.1 India Autoinjectors Market by Type
7.3.4.3.2 India Autoinjectors Market by Application
7.3.4.3.3 India Autoinjectors Market by End Use
7.3.4.4 South Korea Autoinjectors Market
7.3.4.4.1 South Korea Autoinjectors Market by Type
7.3.4.4.2 South Korea Autoinjectors Market by Application
7.3.4.4.3 South Korea Autoinjectors Market by End Use
7.3.4.5 Singapore Autoinjectors Market
7.3.4.5.1 Singapore Autoinjectors Market by Type
7.3.4.5.2 Singapore Autoinjectors Market by Application
7.3.4.5.3 Singapore Autoinjectors Market by End Use
7.3.4.6 Malaysia Autoinjectors Market
7.3.4.6.1 Malaysia Autoinjectors Market by Type
7.3.4.6.2 Malaysia Autoinjectors Market by Application
7.3.4.6.3 Malaysia Autoinjectors Market by End Use
7.3.4.7 Rest of Asia Pacific Autoinjectors Market
7.3.4.7.1 Rest of Asia Pacific Autoinjectors Market by Type
7.3.4.7.2 Rest of Asia Pacific Autoinjectors Market by Application
7.3.4.7.3 Rest of Asia Pacific Autoinjectors Market by End Use
7.4 LAMEA Autoinjectors Market
7.4.1 LAMEA Autoinjectors Market by Type
7.4.1.1 LAMEA Disposable autoinjectors Market by Country
7.4.1.2 LAMEA Reusable autoinjectors Market by Country
7.4.2 LAMEA Autoinjectors Market by Application
7.4.2.1 LAMEA Anaphylaxis Market by Country
7.4.2.2 LAMEA Rheumatoid Arthritis Market by Country
7.4.2.3 LAMEA Multiple Sclerosis Market by Country
7.4.2.4 LAMEA Other Application Market by Country
7.4.3 LAMEA Autoinjectors Market by End Use
7.4.3.1 LAMEA Hospitals & Clinics Autoinjectors Market by Country
7.4.3.2 LAMEA Home care settings Autoinjectors Market by Country
7.4.4 LAMEA Autoinjectors Market by Country
7.4.4.1 Brazil Autoinjectors Market
7.4.4.1.1 Brazil Autoinjectors Market by Type
7.4.4.1.2 Brazil Autoinjectors Market by Application
7.4.4.1.3 Brazil Autoinjectors Market by End Use
7.4.4.2 Argentina Autoinjectors Market
7.4.4.2.1 Argentina Autoinjectors Market by Type
7.4.4.2.2 Argentina Autoinjectors Market by Application
7.4.4.2.3 Argentina Autoinjectors Market by End Use
7.4.4.3 UAE Autoinjectors Market
7.4.4.3.1 UAE Autoinjectors Market by Type
7.4.4.3.2 UAE Autoinjectors Market by Application
7.4.4.3.3 UAE Autoinjectors Market by End Use
7.4.4.4 Saudi Arabia Autoinjectors Market
7.4.4.4.1 Saudi Arabia Autoinjectors Market by Type
7.4.4.4.2 Saudi Arabia Autoinjectors Market by Application
7.4.4.4.3 Saudi Arabia Autoinjectors Market by End Use
7.4.4.5 South Africa Autoinjectors Market
7.4.4.5.1 South Africa Autoinjectors Market by Type
7.4.4.5.2 South Africa Autoinjectors Market by Application
7.4.4.5.3 South Africa Autoinjectors Market by End Use
7.4.4.6 Nigeria Autoinjectors Market
7.4.4.6.1 Nigeria Autoinjectors Market by Type
7.4.4.6.2 Nigeria Autoinjectors Market by Application
7.4.4.6.3 Nigeria Autoinjectors Market by End Use
7.4.4.7 Rest of LAMEA Autoinjectors Market
7.4.4.7.1 Rest of LAMEA Autoinjectors Market by Type
7.4.4.7.2 Rest of LAMEA Autoinjectors Market by Application
7.4.4.7.3 Rest of LAMEA Autoinjectors Market by End Use

Chapter 8. Company Profiles
8.1 Eli Lilly and Company
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Geographical Expansions:
8.2 GlaxoSmithKline PLC (GSK)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.1 Recent strategies and developments:
8.2.1.1 Approvals:
8.3 Merck Group
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.4 Sanofi S.A.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Approvals:
8.4.5.3 Product Launches and Product Expansions:
8.5 Becton, Dickinson and Company
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Product Launches and Product Expansions:
8.6 Teva Pharmaceutical Industries Ltd.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Product Launches and Product Expansions:
8.6.5.3 Approvals:
8.7 Amgen, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Research & Development Expense
8.7.4 Recent strategies and developments:
8.7.4.1 Product Launches and Product Expansions:
8.8 Ypsomed AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.9 AbbVie, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.10. Biogen, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 Recent strategies and developments:
8.10.5.1 Partnerships, Collaborations, and Agreements:
Note: Product cover images may vary from those shown
  • Eli Lilly and Company
  • GlaxoSmithKline PLC (GSK)
  • Merck Group
  • Sanofi S.A.
  • Becton, Dickinson and Company
  • Teva Pharmaceuticals Industries Ltd.
  • Amgen, Inc.
  • Ypsomed AG
  • AbbVie, Inc.
  • Biogen, Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll